Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BIIB
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Biogen Inc. stock price ended at $214.82 on Tuesday, after losing 0.316%.
(Updated on Apr 30, 2024)

Hold candidate since Apr 24, 2024 Gain 6.35% PDF

The Biogen Inc. stock price fell by -0.316% on the last day (Tuesday, 30th Apr 2024) from $215.50 to $214.82. During the last trading day the stock fluctuated 1.94% from a day low at $213.58 to a day high of $217.73. The price has been going up and down for this period, and there has been a 10.08% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -834 thousand shares and in total, 1 million shares were bought and sold for approximately $262.58 million.

Given the current short-term trend, the stock is expected to fall -16.68% during the next 3 months and, with a 90% probability hold a price between $154.12 and $178.99 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

BIIB Signals & Forecast

The Biogen Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $204.42 and $208.61. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday, April 18, 2024, and so far it has risen 12.75%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Biogen Inc. stock

Biogen Inc. finds support from accumulated volume at $208.90 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $4.15 between high and low, or 1.94%. For the last week, the stock has had daily average volatility of 3.97%.

Our recommended stop-loss: $206.87 (-3.70%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 8 days ago.)

Trading Expectations (BIIB) For The Upcoming Trading Day Of Wednesday 1st

For the upcoming trading day on Wednesday, 1st we expect Biogen Inc. to open at $215.38, and during the day (based on 14 day Average True Range), to move between $209.12 and $220.52, which gives a possible trading interval of +/-$5.70 (+/-2.65%) up or down from last closing price. If Biogen Inc. takes out the full calculated possible swing range there will be an estimated 5.31% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $219.31 (2.09%) than the support at $208.90 (2.76%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Biogen Inc. stock A Buy?

Biogen Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: 0.000 Hold/Accumulate Unchanged

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Predicted Opening Price for Biogen Inc. of Wednesday, May 1, 2024

Fair opening price May 1, 2024 Current price
$215.38 ( 0.259%) $214.82

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for BIIB

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 219.53 2.19 %
R2 217.94 1.45 %
R1 216.96 1.00 %
Current price: 214.82
Support S1 213.79 -0.479 %
S2 212.81 -0.93 %
S3 211.23 -1.67 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 226.65 5.51 %
R2 220.74 2.76 %
R1 219.31 2.09 %
Current price 214.82
Support S1 208.90 -2.76%
S2 201.99 -5.97%
S3 194.38 -9.51%

FAQ

What is the symbol for Biogen Inc. Stock and on which exchange is it traded?
The symbol for Biogen Inc. is BIIB and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Biogen Inc. Stock?
Biogen Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Biogen Inc. Stock?
Biogen Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Biogen Inc. Stock.

What's the current price of Biogen Inc. Stock?
As of the end of day on the Apr 30, 2024, the price of an Biogen Inc. (BIIB) share was $214.82.

What is the 52-week high and low for Biogen Inc. Stock?
The 52-week high for Biogen Inc. Stock is $319.76 and the 52-week low is $189.44.

What is the market capitalization of Biogen Inc. Stock?
As of the Apr 30, 2024, the market capitalization of Biogen Inc. is 31.376B.

When is the next earnings date for Biogen Inc.?
The upcoming earnings date for Biogen Inc. is Jul 23, 2024.
Click to get the best stock tips daily for free!

About Biogen Inc.

Biogen. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad... BIIB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT